Cefaly is one of the most commercially established players in consumer-accessible neuromodulation, with OTC trigeminal nerve stimulation for migraine backed by regulatory clearance and direct-to-consumer distribution. Its strong brand and clinical validation create a defensible position, though its modality is limited to a single nerve target compared to broader neuromodulation platforms.